ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis - ACR Meeting Abstracts

Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF inhibitor therapy. However, despite a low disease activity measured by BASDAI, some patients complain of pain or are found in high inflammatory status. In such cases, other disease activity measurement […]

Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis

Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis - ScienceDirect

The Bath Ankylosing Spondylitis Functional Index's History & Patient View - The Rheumatologist

PDF) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Frontiers Non-steroidal Anti-inflammatory Drugs Are Unlikely to Inhibit Radiographic Progression of Ankylosing Spondylitis: A Systematic Review

Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice - ACR Meeting Abstracts

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study - ACR Meeting Abstracts

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index - ACR Meeting

PDF) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy